MHC class II invariant chain–adjuvanted viral vectored vaccines enhances T cell responses in humans

@article{Esposito2020MHCCI,
  title={MHC class II invariant chain–adjuvanted viral vectored vaccines enhances T cell responses in humans},
  author={I. Esposito and P. Cicconi and A. M. D’Alise and Anthony Brown and Marialuisa Esposito and Leo Swadling and P. Holst and M. R. Bassi and Mariano Stornaiuolo and F. Mori and V. Vassilev and Wenqin Li and T. Donnison and C. Gentile and Bethany Turner and Annette von Delft and M. del Sorbo and F. Barra and A. M. Contino and A. Abbate and E. Novellino and A. Thomsen and J. Christensen and A. Lahm and F. Grazioli and V. Ammendola and L. Siani and S. Colloca and P. Klenerman and A. Nicosia and L. Dorrell and A. Folgori and S. Capone and E. Barnes},
  journal={Science Translational Medicine},
  year={2020},
  volume={12}
}
Administration of an MHC class II invariant chain–adjuvanted HCV vaccine in humans leads to enhanced immunogenicity via the proteasome pathway. Tempting T cells Strategies to induce T cell responses during vaccination are difficult to execute. Esposito et al. tested a vaccine that uses the MHC class II invariant chain (Ii), important for antigen presentation to T cells, as an adjuvant in healthy volunteers. The prime-boost strategy involved viral vectors and nonstructural antigens from… Expand
2 Citations

References

SHOWING 1-10 OF 57 REFERENCES
Fusion of HCV nonstructural antigen to MHC class II-associated invariant chain enhances T-cell responses induced by vectored vaccines in nonhuman primates.
Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene.
Vaccination against Lymphocytic Choriomeningitis Virus Infection in MHC Class II-Deficient Mice
...
1
2
3
4
5
...